A Randomized Trial of Progesterone in Women with Recurrent Miscarriages
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Progesterone is essential for the maintenance of pregnancy. However, whether progesterone supplementation in the first trimester of pregnancy would increase the rate of live births among women with a history of unexplained recurrent miscarriages is uncertain. METHODS: We conducted a multicenter, double-blind, placebo-controlled, randomized trial to investigate whether treatment with progesterone would increase the rates of live births and newborn survival among women with unexplained recurrent miscarriage. We randomly assigned women with recurrent miscarriages to receive twice-daily vaginal suppositories containing either 400 mg of micronized progesterone or matched placebo from a time soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) through 12 weeks of gestation. The primary outcome was live birth after 24 weeks of gestation. RESULTS: A total of 1568 women were assessed for eligibility, and 836 of these women who conceived naturally within 1 year and remained willing to participate in the trial were randomly assigned to receive either progesterone (404 women) or placebo (432 women). The follow-up rate for the primary outcome was 98.8% (826 of 836 women). In an intention-to-treat analysis, the rate of live births was 65.8% (262 of 398 women) in the progesterone group and 63.3% (271 of 428 women) in the placebo group (relative rate, 1.04; 95% confidence interval [CI], 0.94 to 1.15; rate difference, 2.5 percentage points; 95% CI, -4.0 to 9.0). There were no significant between-group differences in the rate of adverse events. CONCLUSIONS: Progesterone therapy in the first trimester of pregnancy did not result in a significantly higher rate of live births among women with a history of unexplained recurrent miscarriages. (Funded by the United Kingdom National Institute of Health Research; PROMISE Current Controlled Trials number, ISRCTN92644181.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Caution should be exercised when interpreting the results of these meta-analyses due to differences in the RCTs included in the analyses.199,200”
From Recurrent MiscarriageGreen‐top Guideline No. 17 (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kumar, A., Begum, N., Prasad, S., Aggarwal, S., & Sharma, S. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.07.1251 · Cited by 93
RetractedPeto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Evaluation and treatment of recurrent pregnancy loss: a committee opinion
(2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.048 · Cited by 1,308
Rai, R., & Regan, L. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69204-0 · Cited by 1,227
Self-citationProgesterone and the Risk of Preterm Birth among Women with a Short Cervix
Fonseca, E. B., Celik, E., Parra, M., Singh, M., & Nicolaides, K. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067815 · Cited by 1,086
da Fonseca, E. B., Bittar, R. E., Carvalho, M. H. B., & Zugaib, M. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.41 · Cited by 789
Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study
Stephenson, M. D. (2002) · Human Reproduction · doi:10.1093/humrep/17.2.446 · Cited by 522
A comparison of placental development and endocrine functions between the human and mouse model
Malassine, A., Frendo, J. L., & Evain-Brion, D. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg043 · Cited by 476
Targeted drug delivery in gynaecology: the first uterine pass effect
Bulletti, C., de Ziegler, D., Flamigni, C., Giacomucci, E., Polli, V., Bolelli, G., & Franceschetti, F. (1997) · Human Reproduction · doi:10.1093/humrep/12.5.1073 · Cited by 245
Progestogen for preventing miscarriage
Oates-Whitehead, R., Haas, D., & Carrier, J. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511 · Cited by 224
Research works printed but not linked: 2
- Haas DM, 2013, Cochrane Database Syst Rev, 10, CD003511
- Levine L, 1964, West J Surg Obs Gynecol, 72, 30
Cited by
ESHRE guideline: recurrent pregnancy loss
The ESHRE Guideline Group on RPL, Bender Atik, R., Christiansen, O. B., Elson, J., Kolte, A. M., Lewis, S., Middeldorp, S., Nelen, W., Peramo, B., Quenby, S., et al. (2018) · Human Reproduction Open · doi:10.1093/hropen/hoy004 · Cited by 1,002
“Vaginal progesterone does not improve live birth rates in women with unexplained RPL (Coomarasamy et al., 2015) (Saccone et al.”
InfluentialSelf-citationDimitriadis, E., Menkhorst, E., Saito, S., Kutteh, W. H., & Brosens, J. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00228-z · Cited by 702
Recurrent pregnancy loss: current perspectives
El Hachem, H., Crepaux, V., May-Panloup, P., Descamps, P., Legendre, G., & Bouet, P.-E. (2017) · International Journal of Women's Health · doi:10.2147/ijwh.s100817 · Cited by 462
“151 More recently, a meta-analysis of 10 RCTs including 1,586 women with URPL found a significantly lower risk of recurrent miscarriage (RR: 0.72, 95% CI: 0.53–0.97) and a higher chance of live birth (RR: 1.07, 95% CI: 1.02–1.15) following supplementation with progesterone.”
BackgroundInfluentialESHRE guideline: recurrent pregnancy loss: an update in 2022
The ESHRE Guideline Group on RPL, Bender Atik, R., Christiansen, O. B., Elson, J., Kolte, A. M., Lewis, S., Middeldorp, S., Mcheik, S., Peramo, B., Quenby, S., et al. (2022) · Human Reproduction Open · doi:10.1093/hropen/hoad002 · Cited by 417
Self-citationEndometrial function in women with polycystic ovary syndrome: a comprehensive review
Palomba, S., Piltonen, T. T., & Giudice, L. C. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmaa051 · Cited by 372
A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy
Coomarasamy, A., Devall, A. J., Cheed, V., Harb, H., Middleton, L. J., Gallos, I. D., Williams, H., Eapen, A. K., Roberts, T., Ogwulu, C. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813730 · Cited by 197
Self-citationRecurrent miscarriage: evidence to accelerate action
Coomarasamy, A., Dhillon-Smith, R. K., Papadopoulou, A., Al-Memar, M., Brewin, J., Abrahams, V. M., Maheshwari, A., Christiansen, O. B., Stephenson, M. D., Goddijn, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00681-4 · Cited by 180
Self-citationMekinian, A., Cohen, J., Alijotas‐Reig, J., Carbillon, L., Nicaise‐Roland, P., Kayem, G., Daraï, E., Fain, O., & Bornes, M. (2016) · American Journal of Reproductive Immunology · doi:10.1111/aji.12493 · Cited by 174
Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence
Coomarasamy, A., Devall, A. J., Brosens, J. J., Quenby, S., Stephenson, M. D., Sierra, S., Christiansen, O. B., Small, R., Brewin, J., Roberts, T. E., et al. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.12.006 · Cited by 163
Self-citationRecurrent MiscarriageGreen‐top Guideline No. 17
Regan, L., Rai, R., Saravelos, S., Li, T., & the Royal College of Obstetricians and Gynaecologists (2023) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17515 · Cited by 158
Self-citationProgesterone in normal and pathological pregnancy
Renzo, G. C. D., Giardina, I., Clerici, G., Brillo, E., & Gerli, S. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0038 · Cited by 182
“However, a secondary outcome demonstrated that vaginal progesterone was safe for the mother and the fetus, due to no statistical significant difference in frequency of adverse events between treatment and placebo [48] (Tables 3 and 4).”
Progestogen for treating threatened miscarriage
Wahabi, H., Fayed, A. A., Esmaeil, S. A., & Alzeidan, R. A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005943.pub4 · Cited by 148
Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology
Haas, D. M., Hathaway, T. J., & Ramsey, P. S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511.pub4 · Cited by 130
Saccone, G., Schoen, C., Franasiak, J. M., Scott, R. T., & Berghella, V. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.031 · Cited by 128
Melo, P., Chung, Y., Pickering, O., Price, M. J., Fishel, S. B., Khairy, M., Kingsland, C. R., Lowe, P., Πέτσας, Γ., Rajkhowa, M., et al. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.07.002 · Cited by 137
Self-citationToth, B., Würfel, W., Bohlmann, M., Zschocke, J., Rudnik-Schöneborn, S., Nawroth, F., Schleußner, E., Rogenhofer, N., Wischmann, T., von Wolff, M., et al. (2018) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0586-4568 · Cited by 119
“In the PROMISE trial, a total of 836 women with idiopathic RM were randomized to receive either placebo or 400 mg micronized progesterone applied by vaginal suppository [151].”
Sheikh, J., Allotey, J., Kew, T., Fernández-Félix, B. M., Zamora, J., Khalil, A., Thangaratinam, S., Abdollahain, M., Savitri, A. I., Salvesen, K. Å., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01191-6 · Cited by 108
Self-citationProgestogens for preventing miscarriage: a network meta-analysis
Devall, A., Papadopoulou, A., Podesek, M., Haas, D. M., Price, M. J., Coomarasamy, A., & Gallos, I. D. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013792.pub2 · Cited by 146
“Comparison 4: Recurrent miscarriage: Vaginal micronized progesterone versus placebo, Outcome 7: Adverse drug events Study or Subgroup Coomarasamy 2015 Total (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 1.65 (P = 0.10) Test for subgroup differences: Not…”
BackgroundMethodInfluentialSelf-citationDiagnosis and treatment of luteal phase deficiency: a committee opinion
(2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.02.010 · Cited by 124
“However, in another study, progesterone supplementation initiated after a positive pregnancy test was not shown to decrease miscarriage risk (74).”
Recurrent pregnancy loss: A summary of international evidence-based guidelines and practice
Li, Y. H., & Marren, A. J. (2018) · Australian Journal of General Practice · doi:10.31128/ajgp-01-18-4459 · Cited by 150
Genome Sequencing Explores Complexity of Chromosomal Abnormalities in Recurrent Miscarriage
Dong, Z., Yan, J., Xu, F., Yuan, J., Jiang, H., Wang, H., Chen, H., Zhang, L., Ye, L., Xu, J., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.10.003 · Cited by 107
Knowledge, attitudes, and practice regarding medication use in pregnant women in Southern Italy
Navaro, M., Vezzosi, L., Santagati, G., Angelillo, I. F., & Collaborative Working Group (2018) · PLoS ONE · doi:10.1371/journal.pone.0198618 · Cited by 97
Progestogen for treating threatened miscarriage
Wahabi, H. A., Fayed, A. A., Esmaeil, S. A., & Bahkali, K. H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005943.pub5 · Cited by 95
Sporadic miscarriage: evidence to provide effective care
Coomarasamy, A., Gallos, I. D., Papadopoulou, A., Dhillon-Smith, R. K., Al-Memar, M., Brewin, J., Christiansen, O. B., Stephenson, M. D., Oladapo, O. T., Wijeyaratne, C. N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00683-8 · Cited by 84
Self-citationModern management of recurrent miscarriage
Homer, H. A. (2018) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12920 · Cited by 102
New insights into the mechanisms underlying recurrent pregnancy loss
Ewington, L. J., Tewary, S., & Brosens, J. J. (2018) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13837 · Cited by 81
“RPL patients assigned to the placebo group.(5) In RPL, the incidence of euploid fetal loss increases with each additional miscarriage, whereas the likelihood of a future successful pregnancy gradually decreases.”
BackgroundThe pharmacodynamics and safety of progesterone
Piette, P. C. M. (2020) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2020.06.002 · Cited by 81
Sporadic pregnancy loss and recurrent miscarriage
Devall, A., & Coomarasamy, A. (2020) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2020.09.002 · Cited by 93
Self-citationYamada, H., Deguchi, M., Saito, S., Takeshita, T., Mitsui, M., Saito, T., Nagamatsu, T., Takakuwa, K., Nakatsuka, M., Yoneda, S., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101527 · Cited by 75
Dodd, J. M., Grivell, R. M., O’Brien, C. M., Dowswell, T., & Deussen, A. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012024.pub2 · Cited by 86
Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology
Haas, D. M., Hathaway, T. J., & Ramsey, P. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511.pub5 · Cited by 75
Unexplained recurrent pregnancy loss: Novel causes and advanced treatment
Yu, N., Kwak-Kim, J. Y.-H., & Bao, S. (2022) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2022.103785 · Cited by 76
The rate of euploid miscarriage is increased in the setting of adenomyosis
Stanekova, V., Woodman, R. J., & Tremellen, K. P. (2018) · Human Reproduction Open · doi:10.1093/hropen/hoy011 · Cited by 81
“Similar findings have been reported in the setting of recurrent miscarriage, where progesterone support was also ineffective in preventing miscarriage in patients unselected for adenomyosis status (Coomarasamy et al., 2015).”
ResultHydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage
MOREUIL, C. D., Alavi, Z., & Pasquier, É. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14131 · Cited by 72
“, progesterone), have been tested.(32,65) To date, no treatment”
BackgroundLuteal phase support in assisted reproductive technology
Garg, A., Zielinska, A. P., Yeung, A. C., Abdelmalak, R., Chen, R., Hossain, A., Israni, A., Nelson, S. M., Babwah, A. V., Dhillo, W. S., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00921-5 · Cited by 72
“The PROMISE trial in women with recurrent miscarriage also did not corroborate these findings 109 .”
Building an evidence base for IVF ‘add-ons’
Macklon, N., Ahuja, K. K., & Fauser, B. C. J. M. (2019) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2019.04.005 · Cited by 72
Dydrogesterone use in early pregnancy
Mirza, F., Patki, A. S., & Pexman-Fieth, C. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1121982 · Cited by 76
“In the study by Coomarasamy and colleagues [49], women up to 39 years of age were enrolled after a positive urinary pregnancy test and before 6 weeks of gestation.”
MethodResultInfluentialMlyczyńska, E., Kieżun, M., Kurowska, P., Dawid, M., Pich, K., Respekta, N., Daudon, M., Rytelewska, E., Dobrzyń, K., Kamińska, B., et al. (2022) · Cells · doi:10.3390/cells11060957 · Cited by 70
“These disturbances have a negative impact on endometrium growth and its secretory activities, causing miscarriages or preterm delivery [4,5].”
BackgroundMonastra, G., Grazia, S. D., Mıçılı, S. Ç., Göker, A., & Unfer, V. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1200556 · Cited by 60
“multicenter, double-blind, placebo-controlled, randomized trial [168] did not support some earlier studies that suggested a benefit of progesterone therapy, by vaginal route, in the first”
ResultStephenson, M. D., McQueen, D. B., Winter, M., & Kliman, H. J. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.11.029 · Cited by 65
“that included a more heterogeneous cohort without evaluation of the endometrium (13).”
BackgroundMethodXin, Q., Kong, S., Yan, J., Qiu, J., He, B., Zhou, C., Ni, Z., Bao, H., Huang, L., Lu, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92862 · Cited by 62
Care prior to and during subsequent pregnancies following stillbirth for improving outcomes
Wojcieszek, A. M., Shepherd, E., Middleton, P., Lassi, Z. S., Wilson, T., Murphy, M. M., Heazell, A. E., Ellwood, D. A., Silver, R. M., & Flenady, V. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012203.pub2 · Cited by 55
Success after failure: the role of endometrial stem cells in recurrent miscarriage
Lucas, E. S., Dyer, N. P., Fishwick, K. J., Ott, S., & Brosens, J. J. (2016) · Reproduction · doi:10.1530/rep-16-0306 · Cited by 60
“For example, several randomized control trials on recurrent miscarriage, defined here as three consecutive pregnancy losses, reported life births rate of 65% or more in the placebo group (Coomarasamy et al. 2015, Pasquier et al. 2015).”
Recurrent pregnancy loss: what is the impact of consecutive versus non-consecutive losses?
Egerup, P., Kolte, A. M., Larsen, E. C., Krog, M. C., Nielsen, H. S., & Christiansen, O. B. (2016) · Human Reproduction · doi:10.1093/humrep/dew169 · Cited by 60
Weathering the storm; a review of pre-pregnancy stress and risk of spontaneous abortion
Frazier, T., HOGUE, C. J. R., Bonney, E. A., Yount, K. M., & Pearce, B. D. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.03.001 · Cited by 63
Treatment efficacy for idiopathic recurrent pregnancy loss – a systematic review and meta‐analyses
Roepke, E. R., Hellgren, M., Hjertberg, R., Blomqvist, L., Matthiesen, L., Hénic, E., Lalitkumar, S., & Strandell, A. (2018) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13352 · Cited by 60
“A large RCT (n = 836) compared vaginal progesterone with placebo (36).”
BackgroundSugiura‐Ogasawara, M., Ebara, T., Yamada, Y., Shoji, N., Matsuki, T., Kano, H., Kurihara, T., Omori, T., Tomizawa, M., Miyata, M., et al. (2019) · American Journal of Reproductive Immunology · doi:10.1111/aji.13072 · Cited by 51
Haller, M., Yin, Y., & Ma, L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907652116 · Cited by 54
“Although the decidual response is irrefutably dependent on the presence of progesterone, prospective clinical trials of exogenous progesterone supplementation in pregnant women with a history of recurrent pregnancy loss showed little to no effect on the subsequent rate of live births (17).”
BackgroundProgesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT
Coomarasamy, A., Harb, H. M., Devall, A., Cheed, V., Roberts, T. E., Goranitis, I., Ogwulu, C. B., Williams, H., Gallos, I. D., Eapen, A. K., et al. (2020) · Health Technology Assessment · doi:10.3310/hta24330 · Cited by 57
“Preterm births (≥ 24 weeks and < 34 weeks) 1 (1–2), 83 1 (1–1), 90 Medical history Usual length of menstrual cycle (days), median (IQR), n 28 (28–30), 1947 28 (28–30), 1928 Polycystic ovaries, n/N (%) 226/2077 (11) 227/2072 (11) Fibroids, n/N (%) 100/2077 (5) 78/2072 (4) Endometriosis, n/N (%) 78/2077 (4) 68/2072 (3)…”
BackgroundInfluentialSelf-citationDuncan, W. C. (2021) · Reproduction and Fertility · doi:10.1530/raf-20-0044 · Cited by 67
Evaluation of Recurrent Pregnancy Loss
de Assis, V., Schenone, C. V., & Ros, S. T. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005498 · Cited by 51
“53,54 There is high-quality evidence demonstrating that beginning progesterone support at the time of recognition of pregnancy does not alter live-birth rates; therefore, we do not recommend beginning progesterone supplementation after a documented positive human chorionic gonadotropin test result.”
BackgroundDodd, J. M., Grivell, R. M., O’Brien, C. M., Dowswell, T., & Deussen, A. R. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012024.pub3 · Cited by 51
Should we stop offering endometrial scratching prior to in vitro fertilization?
Lensen, S. F., Venetis, C. A., Ng, E. H. Y., Young, S. L., Vitagliano, A., Macklon, N. S., & Farquhar, C. M. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.04.017 · Cited by 40
Drug prescribing during pregnancy in a central region of Italy, 2008-2012
Ventura, M., Maraschini, A., D’Aloja, P., Kirchmayer, U., Lega, I., Davoli, M., & Donati, S. (2018) · BMC Public Health · doi:10.1186/s12889-018-5545-z · Cited by 43
“trial in which progestogen had been administered during the first trimester of pregnancy did not result in a significant increase in the rate of live births even among women with a history of unexplained recurrent miscarriages [26].”
BackgroundProgestogens and pregnancy loss
Carp, H. (2018) · Climacteric · doi:10.1080/13697137.2018.1436166 · Cited by 62
Infertility treatments during pregnancy and the risk of autism spectrum disorder in the offspring
Davidovitch, M., Chodick, G., Shalev, V., Eisenberg, V. H., Dan, U., Reichenberg, A., Sandin, S., & Levine, S. Z. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.05.022 · Cited by 41
Liquid chromatography–mass spectrometry applications for quantification of endogenous sex hormones
Gravitte, A., Archibald, T., Cobble, A., Kennard, B., & Brown, S. D. (2020) · Biomedical Chromatography · doi:10.1002/bmc.5036 · Cited by 39
Busnelli, A., Garolla, A., Credico, E. D., D’Ippolito, S., Merola, A., Milardi, D., Pontecorvi, A., Scambia, G., & Simone, N. D. (2023) · Andrology · doi:10.1111/andr.13395 · Cited by 39
“6,7 For many years, both clinicalandscientificinterestshavefocusedonthepossiblefemalerisk factors for RPL. 8 In this context, the integrity of sperm DNA, a measure of chromatin condensation damage, has gained particular attention.”
BackgroundPrior, M., Hibberd, R., Asemota, N., & Thornton, J. (2017) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14506 · Cited by 36
Current management of recurrent pregnancy loss
Chester, M. R., Tirlapur, A. S., & Jayaprakasan, K. M. (2022) · The Obstetrician & Gynaecologist · doi:10.1111/tog.12832 · Cited by 38
Chan, D. M. K., Cheung, K. W., Ko, J. K. Y., Yung, S. S. F., Lai, S. F., Lam, M. T., Ng, D. Y. T., Lee, V. C. Y., Li, R., & Ng, E. H. Y. (2020) · Human Reproduction · doi:10.1093/humrep/deaa327 · Cited by 32
Simons, N. E., Leeuw, M., Hooft, J. V. ’., Limpens, J., Roseboom, T. J., Oudijk, M. A., Pajkrt, E., Finken, M. J. J., & Painter, R. C. (2020) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16582 · Cited by 33
Wang, S., Li, M., Sun, F., Chen, C., Ye, J., Li, D., Qian, J., & Du, M. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9469 · Cited by 30
“As co‐stimulatory signals have important roles in T‐cell function and pregnancy maintenance (18,28), despite the lack of evidence regarding improved outcomes following first‐trimester progesterone therapy in females with a history of RSA (40,41), the results of the present study suggested that P4 may also have an immu…”
BackgroundOutcomes in prevention and management of miscarriage trials: a systematic review
Smith, P., Dhillon‐Smith, R. K., O’Toole, E., Cooper, N., Coomarasamy, A., & Clark, T. J. (2018) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15528 · Cited by 33
Self-citationWatters, M., Noble, M., Child, T. J., & Nelson, S. M. (2019) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2019.10.009 · Cited by 28
Maternal–Fetal Compatibility in Recurrent Pregnancy Loss
Cuadrado-Torroglosa, I., García-Velasco, J. A., & Alecsandru, D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082379 · Cited by 32
“…Progesterone in Recurrent Miscarriage (PROMISE) trial, showed no difference in clinical outcomes when comparing the treated group versus placebo [126], a subsequent meta-analysis of several RCTs did observed better results in terms of miscarriage and live birth rate after progestogen…”
BackgroundResultOdendaal, J., Quenby, S. M., Sammaritano, L. R., Macklon, N., Branch, D. W., & Rosenwaks, Z. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.10.002 · Cited by 28
Self-citationProgestogens in women with threatened miscarriage or recurrent miscarriage: A meta‐analysis
Zhao, Y., D'Souza, R. D., Gao, Y., Hao, Q., Kallas-Silva, L., Steen, J. P., & Guyatt, G. H. (2024) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14829 · Cited by 32
“Eleven studies explicitly reported live births 36–38, 41–44 , 46– 49 ; Table 2 ).”
InfluentialWang, G., Zhang, R., Li, C., & Chen, A. (2021) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2021.1957819 · Cited by 27
Shehata, H. A., Elfituri, A., Doumouchtsis, S. K., Zini, M. E., Ali, A., Jan, H., Ganapathy, R., Divakar, H., & Hod, M. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14717 · Cited by 34
Kurowska, P., Mlyczyńska, E., Dupont, J., & Rak, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186823 · Cited by 29
“Therefore, inappropriate vascularization leads to aberrant CL development and reduces the serum concentration of P4 [3], consequently causing miscarriages [4].”
BackgroundQuantitative proteomic analysis of sperm in unexplained recurrent pregnancy loss
Xue, D., Zhang, Y., Wang, Y., Wang, J., An, F., Sun, X., & Yu, Z. (2019) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-019-0496-5 · Cited by 26
Estradiol cypionate aided treatment for experimentally induced ascending placentitis in mares
Curcio, B. D. R., Canisso, I. F., Pazinato, F. M., Borba, L. A., Feijó, L. S., Müller, V. S., Finger, I. S., Toribio, R. E., & Nogueira, C. E. W. (2017) · Theriogenology · doi:10.1016/j.theriogenology.2017.03.010 · Cited by 23
Siemienowicz, K. J., Wang, Y., Marečková, M., Nio‐Kobayashi, J., Fowler, P., Rae, M. T., & Duncan, W. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-78976-x · Cited by 23
CHECK, D. L., & Check, J. H. (2020) · Gynecology & Reproductive Health · doi:10.33425/2639-9342.1139 · Cited by 33
“Such a study was published in the New England Journal of Medicine (NEJM), The PROMISE study [55].”
BackgroundKuroda, K., Ikemoto, Y., Horikawa, T., Moriyama, A., Ojiro, Y., Takamizawa, S., Uchida, T., Nojiri, S., Nakagawa, K., & Sugiyama, R. (2021) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12412 · Cited by 26
Yamada, H., Deguchi, M., Saito, S., Takeshita, T., Mitsui, M., Saito, T., Nagamatsu, T., Takakuwa, K., Nakatsuka, M., Yoneda, S., et al. (2023) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2023.103977 · Cited by 23
Prevention of Pregnancy Loss: Combining Progestogen Treatment and Psychological Support
Картлосовна, Т. Н., Domar, A. D., & Bashiri, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051827 · Cited by 27
Progestogens in the prevention of miscarriage
Carp, H. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0058 · Cited by 23
“There is one trial of micronised progesterone in recurrent miscarraige (PROMISE TRIAL) [39].”
BackgroundFeichtinger, M., Wallner, E., Hartmann, B. W., Reiner, A., & Philipp, T. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.09.037 · Cited by 23
Braakhekke, M., Mol, F., Mastenbroek, S., Mol, B. W., & van der Veen, F. (2016) · Human Reproduction · doi:10.1093/humrep/dew286 · Cited by 27
Self-citationMelo, P., Devall, A., Shennan, A. H., Vatish, M., Becker, C. M., Granne, I., Papageorghiou, A. T., Mol, B. W., & Coomarasamy, A. (2023) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17705 · Cited by 20
Self-citationBusnelli, A., Garolla, A., Tersigni, C., Parodi, V., Inversetti, A., Levi-Setti, P. E., Scambia, G., & Simone, N. D. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.12.002 · Cited by 22
Reproductive Endocrinology in Recurrent Pregnancy Loss
Krog, M. C., Nielsen, H. S., Christiansen, O. B., & Kolte, A. M. (2016) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000225 · Cited by 21
Guideline No. 464: Recurrent Pregnancy Loss
Motan, T., Cockwell, H., Elliott, J., Antaki, R., & White, J. S. (2025) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2025.103167 · Cited by 19
Interventions to prevent miscarriage
Dhillon‐Smith, R. K., Melo, P., Kaur, R., Fox, E., Devall, A., Woodhead, N., & Coomarasamy, A. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.08.955 · Cited by 20
Self-citationProgestogens in luteal support
Carp, H. (2020) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2019-0067 · Cited by 27
Dobson, S. J. A., & Jayaprakasan, K. M. (2018) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2018.1424811 · Cited by 18
“Progestogens were also considered prior to the publication of the PROMISE trial, which showed that progesterone supplementation in the first trimester for women with a history of RM did not improve the live birth rates (Coomarasamy et al. 2015).”
BackgroundSome Reflections on IBM Watson and on Women’s Health
Shader, R. I. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.12.008 · Cited by 17
Recurrent pregnancy loss: a committee opinion
Gracia, C. R., Amato, P., Anderson, J., Flyckt, R. L., Hansen, K., Hill, M., Jain, T., Jindal, S., Kalra, S., Pier, B. D., et al. (2026) · Fertility and Sterility · doi:10.1016/j.fertnstert.2026.03.001 · Cited by 29
Guo, H., & Lu, Q. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-2605 · Cited by 18
“In total, 13 studies met the inclusion criteria and were included in the meta-analysis (14,19-30).”
BackgroundInfluentialZhou, J., Li, L., Pan, X., Wang, J., Qi, Q., Sun, H., Li, C., & Wang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.965694 · Cited by 16
“Progesterone or progestogen can reduce miscarriage rate in women, but have little effect on live birth rate (Coomarasamy et al., 2015; Saccone et al., 2017; Ismail et al., 2018).”
BackgroundEvaluation of the Cyclic Endometrium and Benign Endometrial Disorders
Huang, E. C., Crum, C. P., & Hornstein, M. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-44732-4.00016-9 · Cited by 20
Di, X., Hao, Y., Duan, Z., Ma, Y., Cao, Y., Tan, Z., Song, C., & Xiao-hua, L. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01273-1 · Cited by 16
“In addition, given that low progesterone-related luteal insufficiency is the main cause of embryo implantation failure and early embryo loss, routine clinical supplementation of progesterone to URSA patients can prevent miscarriage and prolong gestational age [24].”
BackgroundBraude, P. (2018) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2018.06.018 · Cited by 15
Bordewijk, E. M., Li, W., Gurrin, L. C., Thornton, J., van Wely, M., & Mol, B. W. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.04.018 · Cited by 16
Self-citationLuteal phase HCG support for unexplained recurrent pregnancy loss – a low hanging fruit?
Fox, C. W., Azores-Gococo, D., Swart, L., Holoch, K., Savaris, R. F., Likes, C. E., Miller, P. B. W., Forstein, D. A., & Lessey, B. A. (2016) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2016.11.016 · Cited by 16
Esposito, M., Paulesu, L. R., & Mandalà, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1637570 · Cited by 22
“Evidence for progesterone bene fi cial effects during pregnancy arises from the PROMISE trial (184) and the PRISM trial (185), in which fi rst trimester initiation of vaginal progesterone prevented pregnancy loss, lowering the risk of PE and the risk of pregnancy hypertensive disorders (186).”
Lai, T.-J., Teng, S., Chang, C.-K., & Huang, C. (2024) · Medical Science Monitor · doi:10.12659/msm.943400 · Cited by 17
“…from the randomized, double-blind PROMISE trial that included 836 women showed that progesterone administered vaginally at 12 weeks of pregnancy increased the live birth rate by 3% [39], but the findings were not statistically significant (65.8% versus 63.3%; RR=1.04; 95% CI 0.94-1.15) [39].”
BackgroundResultInfluentialSchindler, A. E. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0028 · Cited by 15
Metadata
- Authors
- Coomarasamy, A., Williams, H., Truchanowicz, E., Seed, P. T., Small, R., Quenby, S., Gupta, P., Dawood, F., Koot, Y. E. M., Bender Atik, R., Bloemenkamp, K. W. M., Brady, R., Briley, A. L., Cavallaro, R., Cheong, Y. C., Chu, J. J., Eapen, A., Ewies, A., Hoek, A., Kaaijk, E. M., Koks, C. A. M., Li, T.-C., MacLean, M., Mol, B. W., Moore, J., Ross, J. A., Sharpe, L., Stewart, J., Vaithilingam, N., Farquharson, R. G., Kilby, M. D., Khalaf, Y., Goddijn, M., Regan, L., & Rai, R.
- Affiliations
- St Thomas' Hospital (GB)
- University of Birmingham (GB)
- Heart of England NHS Foundation Trust (GB)
- University of Warwick (GB)
- Liverpool Womens NHS Foundation Trust (GB)
- University Medical Center Utrecht (NL)
- Leiden University Medical Center (NL)
- Imperial College London (GB)
- Princess Anne Hospital (GB)
- Sandwell & West Birmingham Hospitals NHS Trust (GB)
- University of Groningen (NL)
- OLVG (NL)
- Máxima Medisch Centrum (NL)
- Royal Hallamshire Hospital (GB)
- University Hospital Crosshouse (GB)
- The University of Adelaide (AU)
- Nottingham University Hospitals NHS Trust (GB)
- King's College Hospital NHS Foundation Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Portsmouth Hospitals NHS Trust (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2141-2148
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2236902456
- Cited by
- 312
- References
- 22
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 24 · 2023: 24 · 2022: 22 · 2021: 33 · 2020: 35 · 2019: 28 · 2018: 38 · 2017: 36 · 2016: 30 · 2015: 1
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research (08/38/01)
- Medical Research Council
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- progesterone supplementation, recurrent pregnancy loss, unexplained recurrent spontaneous abortion, first trimester, live birth rate, micronized progesterone, miscarriage, neonatal survival
- MeSH terms
- Abortion, Habitual, Administration, Intravaginal, Adult, Double-Blind Method, Female, Gestational Age, Humans, Pregnancy, Pregnancy Trimester, First, Progesterone, Body Mass Index, Treatment Failure, Live Birth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.